Efficacy and safety of concurrent chemoradiation with nedaplatin or cisplatin for locally advanced cervical cancer

ZHENG Jihua; WANG Hui; XIE Bo; HUANG Xueqin; ZHOU Juan; XU Zhiyong; HUANG Yanze; WEN Yingjuan; ZHANG Weimin

doi:10.3969/j.issn.1009-0460.2016.12.011

Abstract：Objective To compare the efficacy and safety of nedaplatin or cisplatin combined with concurrent radiotherapy in patients with locally advanced cervical cancer.Methods A total of 63 diagnosed stage Ⅰ B2 ～ ⅣA cervical cancer patients were retrospectively reviewed,among whom 29 patients received nedaplatin with concurrent radiation(nedaplatin 40mg/m2 iv once a week for 6 weeks) and 34 patients received cisplatin with concurrent radiation(cisplatin 40mg/m2 iv once a week for 6 weeks).The radiotherapy included pelvis three-dimensional conformal radiotherapy plus brachytherapy,and the total dose of A point was 30 Gy,and while the total dose of three-dimensional conformal radiotherapy was 50/25 f.Results In nedapiatin group,there were 19 cases in CR,9 cases in PR,1 case in PD,and the response rate(RR) was 96.5％.In cisplatin group,there were 28 cases in CR and 6 cases in PR,and the RR was 100.0％.The difference of RR between the two groups had no statistical significance(P＞0.05).The 2-year recurrence-free survival rate and 2-year metastasis-free survival rate in nedaplatin group was 93.1％ and 86.2％,while in cisplatin group they were 91.2％ and 88.2％ (P＞0.05).The main side effects of the two groups were leukopenia,thrombocytopenia,nausea/vomiting and radiation enteritis.The incidence of grade 3-4 nausea/vomiting in nedapiatin group (17.2％) was lower than that in cisplatin group (41.1％) with statistical significance(P＜0.05).No significant differences were found in other side effects.Conclusion Nedaplatin showed similar efficacy as cisplatin in combination with concurrent radiotherapy,and the incidence of digestive tract reaction was lower than cisplatin with good safety.